Skip to main content
SpringerLink
Log in

Is There a Role for Interleukin-2 Gene Transfer in the Management of Acute Leukemia?

  • Conference paper
Book cover Acute Leukemias V

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 37))

  • 71 Accesses

Abstract

The limitations encountered with the administration of high dose exogenous interleukin-2 (IL-2) have triggered the search for alternative immunotherapeutic approaches or delivery modalities. Studies carried out in experimental tumor models suggest that the tumor-genic potential can be reversed following transduction of different cytokine genes into the DNA of the neoplastic cells. Transfer of the IL-2 gene has also been associated with the generation of anti-tumor specificity and anti-tumor memory. These findings have led to the activation of the first clinical vaccination protocols with human tumor cells engineered to release IL-2 in patients suffering from different tumors. Here, we shall report on the feasability of inserting the IL-2 gene into human acute leukemia cells and the possibility of using this approach for the management of patients with acute leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosenberg SA, Lotze MT, Muul LM et al (1987): A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine 316: 889–897

    Article  PubMed  CAS  Google Scholar 

  2. West WH, Tauer KW, Yannelli JR et al (1987): Constant-infusion recombinant intelreukin-2 in adoptive immunotherapy of advanced cancer. New England Journal of Medicine 316: 898–905

    Article  PubMed  CAS  Google Scholar 

  3. Rosenberg SA, Lotze MT, Anyg JC et al. (1989): Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals Surgery 210: 474–484

    Article  CAS  Google Scholar 

  4. Foa R (1994):Does Interleukin-2 have a role in the management of acute leukemia? Journal of Clinical Oncology 11: 1817–1825

    Google Scholar 

  5. Oshimi K, Oshimi Y, Akutsu M et al (1986): Cytotoxicity of interleukin 2 activated lymphocytes for leukemia and lymphoma cells. Blood 68: 938–948

    PubMed  CAS  Google Scholar 

  6. Lotzova E, Savary CA, Herberman RB (1987): Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Research 11: 1059–1066

    Article  PubMed  CAS  Google Scholar 

  7. Fierro MT, Xin-Sheng L, Lusso P et al. (1988): In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2: 50–54

    PubMed  CAS  Google Scholar 

  8. Foa R, Caretto P, Fierro MT et al. (1990): Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. British Journal of Haematology 75: 34–40

    Article  PubMed  CAS  Google Scholar 

  9. Foa R, Caretto P, Tosti S et al. (1990): Induction and persistence of complete remission in a resistant acute myeloid leukemia patient following treatment with recombinant interleukin 2. Leukemia and Lymphoma 1: 113–177

    Article  Google Scholar 

  10. Meloni G, Foa R, Tosti S et al. (1990): IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study. Haematologica 75: 502–505

    PubMed  CAS  Google Scholar 

  11. Foa R, Meloni G, Tosti S et al (1991a): Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British Journal of Haematology 77: 491–496

    Article  CAS  Google Scholar 

  12. Maraninchi D, Blaise D; Viens P et al. (1991): High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78: 2182–2187

    PubMed  CAS  Google Scholar 

  13. Lim SH, Newland AC, Kelsey S et al (1992): Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia — a phase II study. Cancer Immunology and Immunotherapy 34: 337–342

    Article  PubMed  CAS  Google Scholar 

  14. Meloni G, Foa R, Vignetti M et al (1994): Interleukin 2 may induce prolonged remissions in advanced acute myelogenous leukaemia. Blood, in press

    Google Scholar 

  15. Blaise D, Olive D; Stoppa AM et al. (1990) Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 76: 1092–1097

    PubMed  CAS  Google Scholar 

  16. Higuchi CM, Thompson JA, Petersen FB, Bruckner CD, Fefer A (1991): Toxicity and immunomodulatory effects of interleukin-2 after autlogous bone marrow transplantation for hematologic malignancies. Blood 77: 2561–2568

    PubMed  CAS  Google Scholar 

  17. Meloni G, Foa R, Tosti S et al (1992): Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 6: 780–785

    PubMed  CAS  Google Scholar 

  18. Soiffer RJ, Murray C, Cochran K et al (1982): Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplanation. Blood 79: 517–526

    Google Scholar 

  19. Benyunes MC, Massumoto C, Higuchi CM et al. (1993): Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplantation 12: 159–163

    PubMed  CAS  Google Scholar 

  20. Sondel PM, Kohler PC, Hank JA et al. (1988): Clinical and immunological effect of recombinant interleukin 2 given by repetitive cycles to patients with cancer. Cancer Research 48:: 2561–2567

    PubMed  CAS  Google Scholar 

  21. Favrot MC, Combaret V, Negrier S et al. (1990): Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. Journal of Biological Response Modifiers 9: 167–177

    PubMed  CAS  Google Scholar 

  22. Gottlieb DJ, Prentice HG, Heslop HE et al. (1989): Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood 74: 2335–2342

    PubMed  CAS  Google Scholar 

  23. Foa R, Guarini A; Gillio Tos A et al. (1991b): Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with Interleukin 2: Evidence of in vivo lymphokine activated killer cell generation. Cancer Research 51: 964–968

    CAS  Google Scholar 

  24. Heslop HE, Gottlieb DJ, Bianchi ACM et al. (1989): In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 74: 1374–1380

    PubMed  CAS  Google Scholar 

  25. Lissoni B, Barni S, Tancini G et al. (1994): A randomised study with subcutaneous low-dose interleukin-2 alone versus interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. British Journal of Cancer 69: 196–199

    Article  PubMed  CAS  Google Scholar 

  26. Foa R, Guarini A, Cignetti A et al. (1994): Cytokine gene therapy: a new strategy for the management of cancer patients. Natural Immunity 13: 65–75

    PubMed  CAS  Google Scholar 

  27. Colombo MP, Forni G (1994): Cytokine gene transfer inhibition and tentative tumor therapy: where are we now? Immunology Today 15: 48–51

    Article  PubMed  CAS  Google Scholar 

  28. Forni G, Parmiani G, Guarini A, Foa R (1994): Gene transfer in tumor therapy. Annals of Oncology, in press

    Google Scholar 

  29. Fearon ER, Pardoll DM, Itaya T et al. (1990): Interleukin-2 production by tumor cells bypasses T helper function on the generation of an antitumor response. Cell 60: 3997–403

    Article  Google Scholar 

  30. Gansbacher B, Zier K, Daniels B et al. (1990): Interleukin-2 gene tranfer into tumor cells abrogates tumorigenicity and induces protective immunity. Journal of Experimental Medicine 172: 1217–1224

    Article  PubMed  CAS  Google Scholar 

  31. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard L (1991): Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. European Journal of Immunology 21: 851–854

    Article  PubMed  CAS  Google Scholar 

  32. Gansbacher B, Zier K, Cronin K et al. (1992): Retroviral gene tranfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80: 2817–2825

    PubMed  CAS  Google Scholar 

  33. Gastl G, Finstad CL, Guyrini A et al. (1992): Retroviral vector-mediated lymphokine gene transfer into human cancer cells. Cancer Research 52: 6229–6236

    PubMed  CAS  Google Scholar 

  34. Foa R, Guarini A, Gansbacher B (1992): IL2 treatment for cancer: from biology to gene therapy. British Journal of Cancer 66: 992–998

    Article  PubMed  CAS  Google Scholar 

  35. Belldegrun A, Tso C-L, Sakata T et al. (1993): Human renal carcinoma line tranfected with interleukin-2 and/or interferon α gene(s): implications for live cancer vaccines. Journal of the National Cancer Institute 85: 207–216

    Article  PubMed  CAS  Google Scholar 

  36. Guarini A; Gansbacher B, Cronin B et al. (1994): Specific T lymphocyte reactivity to IL-2 gene transduced human melanoma cells. In: Forni G, Foa R, Santoni A, Frati L (eds): Cytokine Induced Tumor Immunogenicity, London, UK: Academic Press, 403–413

    Google Scholar 

  37. Cignetti A, Guarini A; Carbone A et al. (1994): Tranduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. Journal of the National Cancer Insitute 86: 785–791

    Article  CAS  Google Scholar 

  38. Foa R, Fierro MT, Cesano A et al. (1991c): Defensive lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 78: 1041–1046

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Biomediche e Oncologia Umana, Sezione Clinica, Italy

    Robert Foa, Alessandro Cignetti, Anna Gillio Tos, Anna Carbone, Paola Francia do Celle & Anna Guarini

  2. Centro NR Immunogenetica e Oncologia Sperimentale, University of Turin, Turin, Italy

    Robert Foa

Authors
  1. Robert Foa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Cignetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Gillio Tos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Carbone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Francia do Celle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna Guarini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany

    W. Hiddemann  & W. Plunkett  & 

  2. Department of Internal Medicine, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    T. Büchner

  3. Department of Pediatric Oncology, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    J. Ritter

  4. Department of Internal Medicine, MD Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA

    B. Wörmann M.D., Ph.D.  & M. J. Keating M.D., B.S.  & 

  5. Koordinierungsstelle, Deutsche Krebsgesellschaft e.V., Thea-Bähnisch-Weg 12, 30657, Hannover, Germany

    U. Creutzig

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Foa, R., Cignetti, A., Tos, A.G., Carbone, A., do Celle, P.F., Guarini, A. (1996). Is There a Role for Interleukin-2 Gene Transfer in the Management of Acute Leukemia?. In: Hiddemann, W., et al. Acute Leukemias V. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 37. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78907-6_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78907-6_47

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78909-0

  • Online ISBN: 978-3-642-78907-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation